ASH 2023 | Azacitidine and venetoclax plus gilteritinib in the treatment of FLT3-mutated AML
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the potential improvement in outcomes for patients with FLT3-mutated acute myeloid leukemia (AML) by incorporating the FLT3 inhibitor gilteritinib into the azacitidine and venetoclax combination, which was investigated in the VIALE-A trial (NCT02993523). Additionally, Dr Ravandi highlights ongoing research into the completely oral regimen of ASTX727, venetoclax, and gilteritinib for treating older patients with AML. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Prelude: Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Syros: Consultancy, Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Astellas: Consultancy, Honoraria, Research Funding; Xencor: Research Funding; Biomea fusion: Honoraria, Research Funding; Celgene/BMS: Consultancy, Honoraria, Research Funding; Astex/taiho: Membership on an entity’s Board of Directors or advisory committees, Research Funding.
